Phenotypic amikacin resistance may not indicate poor response to amikacin in <i>Mycobacterium avium</i> complex pulmonary disease-Reference-Cited by-同舟云学术

Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease

Published:2024-05-17 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Minuk L. M.¹^ORCID,Brode S. K.¹²³,Mehrabi M.⁴,Sharma M. K.⁵⁶,Stobart M.⁶,Soualhine H.⁵⁶⁷^ORCID,Marras T. K.¹²^ORCID

Affiliation:

1. Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

2. Division of Respirology, Department of Medicine, University Health Network, Mount Sinai Hospital, Toronto, Ontario, Canada

3. Division of Respiratory Medicine, West Park Healthcare Centre, Toronto, Ontario, Canada

4. Division of Respirology, Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada

5. National Reference Centre for Mycobacteriology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

6. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada

7. McGill International TB Centre, McGill University, Montreal, Quebec, Canada

Abstract

ABSTRACT When using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes or rrs gene mutations.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00084-24

Reference17 articles.

1. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

2. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

3. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

4. In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates

5. Underutilization of nontuberculous mycobacterial drug susceptibility testing in Ontario, Canada, 2010–2015